Drug Profile
Gemcitabine elaidate
Alternative Names: CO-1.01; CO-101; CP-4126; Gemcitabine 5'-elaidic acid esterLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Clavis Pharma
- Developer Clavis Pharma; Clovis Oncology
- Class Antineoplastics; Deoxyribonucleosides; Esters; Pyrimidine nucleosides
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in United Kingdom (IV)
- 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in USA (IV)
- 15 Feb 2013 Discontinued - Phase-I for Solid tumours in United Kingdom (IV)